Malta - engelsk - Medicines Authority

smithkline beecham limited 980, great west road, brentford middlesex tw8 9gs, united kingdom - neisseria meningitidis, polysaccharide group, meningococcal polysaccharide, group w - powder and solvent for solution for injection - neisseria meningitidis polysaccharide group c 50 µg meningococcal polysaccharide group w-135 50 µg - vaccines

Malta - engelsk - Medicines Authority

smithkline beecham limited 980, great west road, brentford middlesex tw8 9gs, united kingdom - neisseria meningitidis, polysaccharide group, meningococcal polysaccharide, group w - powder and solvent for solution for injection - neisseria meningitidis polysaccharide group c 50 µg meningococcal polysaccharide group w-135 50 µg - vaccines

Malta - engelsk - Medicines Authority

smithkline beecham limited 980, great west road, brentford middlesex tw8 9gs, united kingdom - neisseria meningitidis, polysaccharide group, meningococcal polysaccharide, group w - powder and solvent for solution for injection - neisseria meningitidis polysaccharide group c 50 µg meningococcal polysaccharide group w-135 50 µg - vaccines

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pneumococcal purified capsular polysaccharides, quantity: 2.2 microgram; pneumococcal purified capsular polysaccharides, quantity: 4.4 microgram - injection, suspension - excipient ingredients: aluminium phosphate; water for injections; polysorbate 80; diphtheria crm197 protein; succinic acid; sodium chloride - active immunisation for the prevention of pneumococcal disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f in adults and children aged more than 6 weeks of age. the use of prevenar 13 should be guided by official recommendations.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - meningococcal polysaccharide group w135, quantity: 10 microgram; meningococcal polysaccharide group c, quantity: 10 microgram; meningococcal polysaccharide group a, quantity: 10 microgram; meningococcal polysaccharide group y, quantity: 10 microgram - injection, solution - excipient ingredients: sodium acetate; tetanus toxoid; sodium chloride; water for injections - menquadfi is indicated for active immunisation for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w and y.,the use of menquadfi should be in accordance with official recommendations.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pneumococcal purified capsular polysaccharides, quantity: 2.2 microgram; pneumococcal purified capsular polysaccharides, quantity: 4.4 microgram - injection, suspension - excipient ingredients: aluminium phosphate; succinic acid; sodium chloride; water for injections; polysorbate 80; diphtheria crm197 protein - active immunisation for the prevention of pneumococcal disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 8, 9v, 10a, 11a, 12f, 14, 15b, 18c, 19a, 19f, 22f, 23f, and 33f in individuals from 6 weeks of age and older.,prevenar 20 may not prevent disease caused by s. pneumoniae serotypes that are not contained in the vaccine.,prevenar 20 should be used in accordance with official recommendations.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - meningococcal polysaccharide 48ug (4 µg of each of groups a, c, y & w-135, each separately conjugated to diphtheria toxoid, 48 µg total) - solution for injection - 4 µg each/0.5 ml - active: meningococcal polysaccharide 48ug (4 µg of each of groups a, c, y & w-135, each separately conjugated to diphtheria toxoid, 48 µg total) excipient: dibasic sodium phosphate monobasic sodium phosphate sodium chloride water for injection - menactra vaccine is indicated for active immunisation in individuals from 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n. meningitidis serogroups a, c, y and w-135. menactra vaccine is not indicated for the prevention of meningitis caused by other microorganisms or for the prevention of invasive meningococcal disease caused by n meningitidis serogroup b. menactra vaccine is not indicated for treatment of meningococcal infections. menactra vaccine is not indicated for immunisation against diphtheria.

Singapore - engelsk - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - meningococcal polysaccharide vaccine groups a, c, y, w-135 - injection, powder, for solution - 50 mcg/ps/0.5 ml - meningococcal polysaccharide vaccine groups a, c, y, w-135 50 mcg/ps/0.5 ml

Malta - engelsk - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - neisseria meningitidis, polysaccharide group, tetanus toxoid - suspension for injection - neisseria meningitidis polysaccharide group c tetanus toxoid - vaccines

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - haemophilus influenza type b polyribose ribitol phosphate,meningococcal polysaccharide group c,tetanus toxoid -